Real-world observational study on pulmonary arterial hypertension: Italian cohort treated with macitentan and/or selexipag as a part of a combination treatment (INSPECTIO)
Vascular Pharmacology · 2026
DOI: 10.1016/j.vph.2026.107585 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Vascular Pharmacology, 2026. Verfasst von Michele D'Alto und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, C.T.O. Hospital, Naples, Italy. Hauptthemen laut MEDLINE: Acetamides, Antihypertensive Agents, Endothelin Receptor Antagonists, Pulmonary Arterial Hypertension. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: Pulmonary arterial hypertension (PAH) is a progressive disease associated with significant morbidity and mortality. Combination therapy targeting multiple pathways has been shown to improve clinical outcomes. METHODS: The INSPECTIO study was a prospective, multicenter, observational study conducted across 29 Italian centers specializing in PAH management. The study sought to explore the impact of combination therapy on disease progression and quality of life, by assessing non-invasive risk parameters, echocardiographic and hemodynamic conditions, and patient-reported outcomes (PROs). Patients with PAH at low or intermediate mortality risk, treated with macitentan and/or selexipag (as monotherapy or in combination), were enrolled. Data on non-invasive low-risk criteria (WHO Functional Class, 6-min walk distance [6MWD], and NT-proBNP), REVEAL risk scores, echocardiographic and hemodynamic parameters, and patient-reported outcomes (emPHasis-10) were collected at baseline and 12 months. A Narrative Medicine analysis complemented quantitative findings by exploring patients' experiences. RESULTS: Among 176 patients with follow-up data, the number of non-invasive low-risk criteria increased by an average of 0.15 at 12 months (p = 0.0167). REVEAL 2.0 and REVEAL Lite 2 scores showed significant reductions (mean changes: -1.0, p = 0.0142; -0.8, p = 0.0111, respectively). Modest changes were observed in echocardiographic and hemodynamic parameters. Narrative analysis highlighted strengthened patient-provider relationships and improved coping strategies. Safety outcomes aligned with known profiles. CONCLUSIONS: The INSPECTIO study supports the effectiveness of guideline-directed therapy and regular risk assessment to optimize treatment strategies in PAH. The increase in non-invasive low-risk criteria suggests a stabilization of disease over 12 months.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, C.T.O. Hospital, Naples, Italy.
- Cardiology Department, IRCCS Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
- Cardiology, Haemodynamic and Cardiac Intensive Care Unit, San Salvatore Hospital, L'Aquila, Italy.
- Cardiology and Cardiac Intensive Care Unit, "Ospedali Riuniti" University Hospital, Ancona, Italy.
- Catholic University of the Sacred Heart - Fondazione Policlinico Universitario A. Gemelli IRCCS, Department of Cardiovascular and Thoracic Sciences, Rome, Italy.
- S.O.D. Clinic of Cardiology and Arithmology, Department of Biomedical Sciences and Public Health, Polytechnic University of Marche, Ancona, Italy.
Zitieren
APA
D'Alto, M., Scelsi, L., Giuliani, L., Perna, G. P., Baldi, F., Guerra, F., Di Poi, E., Vicenzi, M., Badagliacca, R., Corda, M., Airò, E., Ferrero, P., Ameri, P., Bux, F., Agostoni, P., D'Agostino, C., Casu, G., Biancospino, M., Uglietti, A., & De Santis, S. (2026). Real-world observational study on pulmonary arterial hypertension: Italian cohort treated with macitentan and/or selexipag as a part of a combination treatment (INSPECTIO). Vascular Pharmacology. https://doi.org/10.1016/j.vph.2026.107585
Vancouver
D'Alto M, Scelsi L, Giuliani L, Perna GP, Baldi F, Guerra F, et al. Real-world observational study on pulmonary arterial hypertension: Italian cohort treated with macitentan and/or selexipag as a part of a combination treatment (INSPECTIO). Vascular Pharmacology. 2026. doi:10.1016/j.vph.2026.107585
BibTeX
@article{DAlto2026,
author = {D'Alto, Michele and Scelsi, Laura and Giuliani, Livio and Perna, Gian Piero and Baldi, Fabiana and Guerra, Federico and Di Poi, Emma and Vicenzi, Marco and Badagliacca, Roberto and Corda, Marco and Airò, Edoardo and Ferrero, Paolo and Ameri, Pietro and Bux, Francesca and Agostoni, Piergiuseppe and D'Agostino, Carlo and Casu, Gavino and Biancospino, Matteo and Uglietti, Alessia and De Santis, Stefano},
title = {Real-world observational study on pulmonary arterial hypertension: Italian cohort treated with macitentan and/or selexipag as a part of a combination treatment (INSPECTIO)},
journal = {Vascular Pharmacology},
year = {2026},
doi = {10.1016/j.vph.2026.107585}
}
EUVIMED